,Mesenchymal stem cells and immune disorders: from basic science to clinical transition

来源 :医学前沿 | 被引量 : 0次 | 上传用户:dazhonghua988
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
As a promising candidate seed cell type in regenerative medicine,mesenchymal stem cells (MSCs) have attracted considerable attention.The unique capacity of MSCs to exert a regulatory effect on immunity in an autologous/allergenic manner makes them an attractive therapeutic cell type for immune disorders.In this review,we discussed the current knowledge of and advances in MSCs,including its basic biological properties,i.e.,multilineage differentiation,secretome,and immunomodulation.Specifically,on the basis of our previous work,we proposed three new concepts of MSCs,i.e.,“subtotipotent stem cell” hypothesis,MSC system,and “Yin and Yang” balance of MSC regulation,which may bring new insights into our understanding of MSCs.Furthermore,we analyzed data from the Clinical Trials database (http://clinicaltrials.gov) on registered clinical trials using MSCs to treat a variety of immune diseases,such as graft-versus-host disease,systemic lupus erythematosus,and multiple sclerosis.In addition,we highlighted MSC clinical trials in China and discussed the challenges and future directions in the field of MSC clinical application.
其他文献
In December 2019,an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan,Hubei Province,China.By February 14,2020,it has led to 66 492 confirmed patients
Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML).In 2007,a pivotal phase-2 study of dasa